Analysis of infectious complications in infants with acute lymphoblastic leukemia treated on the children's cancer group protocol 1953: A report from the children's oncology group

Journal of Pediatric Hematology/Oncology

Volumn 31, Issue 6, 2009, Pages 398-405

  Salzer, Wanda ^a   Dinndorf, Patricia ^b   Dreyer, Zoann ^c   Hilden, Joanne ^d   Reaman, Gregory H ^e  

^a NATIONAL CANCER INSTITUTE   (United States)

^b CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

^c BAYLOR COLLEGE OF MEDICINE   (United States)

^d Peyton Manning Children's Hospital   (United States)

^e CHILDREN S ONCOLOGY GROUP   (United States)

Author keywords

Infant acute lymphoblastic leukemia; Infection

Indexed keywords

ANTINEOPLASTIC AGENT; DAUNORUBICIN; IMMUNOGLOBULIN;

ACUTE LYMPHOBLASTIC LEUKEMIA; ARTICLE; BACTERIAL INFECTION; CANCER CHEMOTHERAPY; CHILD CARE; CONTINUOUS INFUSION; CONTROLLED STUDY; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; INFANT; INFECTION; INFECTION COMPLICATION; INTENSIVE CARE; MAJOR CLINICAL STUDY; MORTALITY; MUCOSA INFLAMMATION; MYCOSIS; PRIORITY JOURNAL; PROTOZOAL INFECTION; RESPIRATORY TRACT INFECTION; SKIN DISEASE; TREATMENT OUTCOME; VIRUS INFECTION;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; HUMANS; INFANT; INFECTION; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; RETROSPECTIVE STUDIES;

EID: 67651222632     PISSN: 10774114     EISSN: 15363678     Source Type: Journal    
DOI: 10.1097/MPH.0b013e3181a6dec0     Document Type: Article

References (45)

1. US Cancer Statistics Working Group. United States Cancer Statistics: 1999-2004 Incidence and Mortality Web-based Report. Atlanta; 2007. Available at: www.cdc.gov/uscs.
2. Martin J, Hamilton B, Sutton P, et al. Births: Final data for 2005. National Vital Statistics Reports. Hyattsville, MD: National Center for Health Staistics; 2007.
3. Ferster A, Bertrand Y, Benoit Y, et al. Improved survival for acute lymphoblastic leukaemia in infancy: the experience of EORTC-Childhood Leukaemia Cooperative Group. Br J Haematol. 1994;86:284-290.
4. Chessells JM, Eden OB, Bailey CC, et al. Acute lymphoblastic leukaemia in infancy: experience in MRC UKALL trials. Report from the Medical Research Council Working Party on Childhood Leukaemia. Leukemia. 1994;8:1275-1279.
5. Silverman LB, McLean TW, Gelber RD, et al. Intensified therapy for infants with acute lymphoblastic leukemia: results from the Dana-Farber Cancer Institute Consortium. Cancer. 1997;80:2285-2295.
6. Frankel LS, Ochs J, Shuster JJ, et al. Therapeutic trial for infant acute lymphoblastic leukemia: the Pediatric Oncology Group experience (POG 8493). J Pediatr Hematol Oncol. 1997;19:35-42.
7. Dordelmann M, Reiter A, Borkhardt A, et al. Prednisone response is the strongest predictor of treatment outcome in infant acute lymphoblastic leukemia. Blood. 1999;94: 1209-1217.
8. Reaman G, Zeltzer P, Bleyer WA, et al. Acute lymphoblastic leukemia in infants less than one year of age: a cumulative experience of the Children's Cancer Study Group. J Clin Oncol. 1985;3:1513-1521.
9. Reaman GH, Sposto R, Sensel MG, et al. Treatment outcome and prognostic factors for infants with acute lymphoblastic leukemia treated on two consecutive trials of the Children's Cancer Group. J Clin Oncol. 1999;17:445-455.
10. Hilden JM, Dinndorf PA, Meerbaum SO, et al. Analysis of prognostic factors of acute lymphoblastic leukemia in infants: report on CCG 1953 from the Children's Oncology Group. Blood. 2006;108:441-451.
11. Basso G, Putti MC, Cantu-Rajnoldi A, et al. The immunophenotype in infant acute lymphoblastic leukaemia: correlation with clinical outcome. An Italian multicentre study (AIEOP). Br J Haematol. 1992;81:184-191.
12. Cimino G, Rapanotti MC, Rivolta A, et al. Prognostic relevance of ALL-1 gene rearrangement in infant acute leukemias. Leukemia. 1995;9:391-395.
13. Rubnitz JE, Link MP, Shuster JJ, et al. Frequency and prognostic significance of HRX rearrangements in infant acute lymphoblastic leukemia: a Pediatric Oncology Group study. Blood. 1994;84:570-573.
14. Pui CH, Ribeiro RC, Campana D, et al. Prognostic factors in the acute lymphoid and myeloid leukemias of infants. Leukemia. 1996;10:952-956.
15. Hilden JM, Frestedt JL, Moore RO, et al. Molecular analysis of infant acute lymphoblastic leukemia: MLL gene rearrangement and reverse transcriptase-polymerase chain reaction for t (4;11) (q21; q23). Blood. 1995;86:3876-3882.
16. Hurwitz CA, Silverman LB, Schorin MA, et al. Substituting dexamethasone for prednisone complicates remission induction in children with acute lymphoblastic leukemia. Cancer. 2000;88:1964-1969.
17. Dreyer ZE, Dinndorf P, Joanne HM, et al. Unexpected Toxicity with Intensified Induction in Infant Acute Lymphoid Leukemia. ASH Annual Meeting Abstracts. 2007 November 16, 2007;110(11):852.
18. Balis FM, Lester CM, Chrousos GP, et al. Differences in cerebrospinal fluid penetration of corticosteroids: possible relationship to the prevention of meningeal leukemia. J Clin Oncol. 1987;5:202-207.
19. Kamps WA, Veerman AJP, van Wering ER, et al. Long-term follow-up of Dutch Childhood Leukemia Study Group (DCLSG) protocols for children with acute lymphoblastic leukemia, 1984-1991. Leukemia: Nature Publishing Group; 2000:2240.
20. Mitchell CD, Richards SM, Kinsey SE, et al. Benefit of dexamethasone compared with prednisolone for childhood acute lymphoblastic leukaemia: results of the UK Medical Research Council ALL97 randomized trial. Br J Haematol. 2005;129:734-745.
21. Bostrom BC, Gaynon P, Sather H, et al, eds. Dexamethasone decreases central nervous system relapse and improves event free survival in lower risk acute lymphoblastic leukemia. Proc Am Soc Clin Oncol. 1998. Abstract no. 2024.
22. Kaleita TA, Reaman GH, MacLean WE, et al. Neurodevelopmental outcome of infants with acute lymphoblastic leukemia: a Children's Cancer Group report. Cancer. 1999;85:1859-1865.
23. Cornely OA, Bohme A, Buchheidt D, et al. Prophylaxis of invasive fungal infections in patients with hematological malignancies and solid tumors-guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO). Ann Hematol. 2003;82 (suppl 2) :S186-S200 [Epub Sep. 11, 2003].
24. Robenshtok E, Gafter-Gvili A, Goldberg E, et al. Antifungal prophylaxis in cancer patients after chemotherapy or hematopoietic stem-cell transplantation: systematic review and meta-analysis. J Clin Oncol. 2007;25:5471-5489.
25. Maertens J. Evaluating prophylaxis of invasive fungal infections in patients with haematologic malignancies. Eur J Haematol. 2007;78:275-282.
26. Bermudez M, Fuster JL, Llinares E, et al. Itraconazole-related increased vincristine neurotoxicity: case report and review of literature. J Pediatr Hematol Oncol. 2005;27:389-392.
27. van Burik J-AH, Ratanatharathorn V, Stepan DE, et al. Micafungin versus fluconazole for prophylaxis against invasive fungal infections during neutropenia in patients undergoing hematopoietic stem cell transplantation. Clin Infect Dis. 2004;39:1407-1416.
28. Seibel NL, Schwartz C, Arrieta A, et al. Safety, tolerability, and pharmacokinetics of Micafungin (FK463) in febrile neutropenic pediatric patients. Antimicrob Agents Chemo Ther. 2005;49:3317-3324.
29. Maertens J, Deeren D, Dierickx D, et al. Preemptive antifungal therapy: still a way to go. Curr Opin Infect Dis. 2006;19:551-556.
30. Kedzierska A, Kochan P, Pietrzyk A, et al. Current status of fungal cell wall components in the immunodiagnostics of invasive fungal infections in humans: galactomannan, mannan and (1->3) -beta-D-glucan antigens. Eur J Clin Microbiol Infect Dis. 2007;26:755-766.
31. Hayden R, Pounds S, Knapp K, et al. Galactomannan antigenemia in pediatric oncology patients with invasive aspergillosis. Pediatr Infect Dis J. 2008;27:815-819.
32. Steinbach WJ, Addison RM, McLaughlin L, et al. Prospective Aspergillus galactomannan antigen testing in pediatric hematopoietic stem cell transplant recipients. Pediatr Infect Dis J. 2007;26:558-564.
33. Castro M. Treatment and prophylaxis of Pneumocystis carinii pneumonia. Semin Respir Infect. 1998;13:296-303.
34. Warren E, George S, You J, et al. Advances in the treatment and prophylaxis of Pneumocystis carinii pneumonia. Pharmacotherapy. 1997;17:900-916.
35. Warnock AC, Rimland D. Comparison of trimethoprimsulfamethoxazole, dapsone, and pentamidine in the prophylaxis of Pneumocystis carinii pneumonia. Pharmacotherapy. 1996;16:1030-1038.
36. Weinthal J, Frost JD, Briones G, et al. Successful Pneumocystis carinii pneumonia prophylaxis using aerosolized pentamidine in children with acute leukemia. J Clin Oncol. 1994;12:136-140.
37. Mustafa MM, Pappo A, Cash J, et al. Aerosolized pentamidine for the prevention of Pneumocystis carinii pneumonia in children with cancer intolerant or allergic to trimethoprim/sulfamethoxazole. J Clin Oncol. 1994;12:258-261.
38. O'Sullivan BP, Spaulding R. The use of aerosolized pentamidine for prophylaxis of Pneumocystis carinii pneumonia in children with leukemia. Pediatr Pulmonol. 1994;18:228-231.
39. Orcutt TA, Godwin CR, Pizzo PA, et al. Aerosolized pentamidine: a well-tolerated mode of prophylaxis against Pneumocystis carinii pneumonia in older children with human immunodeficiency virus infection. Pediatr Infect Dis J. 1992;11:290-294.
40. Principi N, Marchisio P, Onorato J, et al. Long-term administration of aerosolized pentamidine as primary prophylaxis against Pneumocystis carinii pneumonia in infants and children with symptomatic human immunodeficiency virus infection. The Italian Pediatric Collaborative Study Group on Pentamidine. J Acquir Immune Defic Syndr Hum Retrovirol. 1996;12:158-163.
41. Hand IL, Wiznia AA, Porricolo M, et al. Aerosolized pentamidine for prophylaxis of Pneumocystis carinii pneumonia in infants with human immunodeficiency virus infection. Pediatr Infect Dis J. 1994;13:100-104.
42. The PREVENT Study Group. Reduction of respiratory syncytial virus hospitalization among premature infants and infants with bronchopulmonary dysplasia using respiratory syncytial virus immune globulin prophylaxis. Pediatrics. 1997;99:93-99.
43. Meissner HC, Long SS. Revised indications for the use of palivizumab and respiratory syncytial virus immune globulin intravenous for the prevention of respiratory syncytial virus infections. Pediatrics. 2003;112 (6 Pt 1) : 1447-1452.
44. Rennels MB, Meissner HC, Baker CJ, et al. Revised indications for the use of palivizumab and respiratory syncytial virus immune globulin intravenous for the prevention of respiratory syncytial virus infections. Pediatrics. 2003;112:1442-1446.
45. Abramson JS, Baker CJ, Baltimore RS, et al. Recommendations for influenza immunization of children. Pediatrics. 2004;113:1441-1447.